Viral Pathogens and Pulmonary Fibrosis: EMT‐Driven Mechanisms and Insights From Traditional Chinese Medicine
Open Access
- 26 February 2026
- journal article
- review article
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (2) , e70118
Abstract
Idiopathic pulmonary fibrosis (IPF) is a serious progressive complication of the respiratory system, which is profoundly associated with persistent extracellular matrix (ECM) deposition, fibrosis, and disrupted tissue regeneration. Emerging evidence shows that epithelial–mesenchymal transition (EMT) acts as a key factor in the pathogenesis of this idiopathic interstitial lung disease by connecting long‐lasting epithelial damage to fibroblast accumulation and fibrotic processes. Viral pathogens, particularly emerging and re‐emerging viruses, such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), Influenza Virus, and Dengue Virus (DENV) and also those with oncogenic potential such as Epstein–Barr Virus (EBV), Cytomegalovirus (CMV), and Hepatitis C Virus (HCV), have been demonstrated to be significantly associated with impaired epithelial signalling, persistent inflammation, and EMT induction. This underscores the presence of potential mechanistic overlap between viral infections and fibrotic complications of the respiratory system. On the other hand, investigations have also suggested the capacity of Traditional Chinese Medicine (TCM) agents to modulate various EMT‐linked pathways, which are simultaneously involved in both viral infections and IPF development. These common signalling pathways include TGF‐β, Wnt/β‐catenin, PI3K/AKT, and NF‐κB signalling, acting as potential therapeutic targets against fibrotic complications such as IPF. The present review aims to comprehensively describe current evidence on the dynamic cross‐talk between viral pathogens, particularly SARS‐CoV‐2, Influenza Virus, and DENV, EMT, and lung fibrosis. Additionally, it critically discusses how TCM‐derived bioactive agents can interfere with these interconnected processes. This review elucidates the mechanistic basis and therapeutic potential of TCM compounds in lung fibrosis, considering the wider context of virus‐related EMT dysregulation.Keywords
This publication has 138 references indexed in Scilit:
- Changes in Smad expression and subcellular localization in bleomycin-induced pulmonary fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progressionJournal of Clinical Investigation, 2004
- Influence of human T lymphotrophic virus type I on cryptogenic fibrosing alveolitis − HTLV-I associated fibrosing alveolitis: proposal of a new clinical entityClinical and Experimental Immunology, 2003
- Aberrant Wnt/β-Catenin Pathway Activation in Idiopathic Pulmonary FibrosisThe American Journal of Pathology, 2003
- A Rearranged Form of Epstein–Barr Virus DNA Is Associated with Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2002
- The Epstein–Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferasesProceedings of the National Academy of Sciences, 2002
- Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosisThorax, 2000
- The Detection of Epstein-Barr Virus DNA in Lung Tissue from Patients with Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Idiopathic Pulmonary Fibrosis and High Prevalence of Serum Antibodies to Hepatitis C VirusAmerican Review of Respiratory Disease, 1992
- Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type 1 tax: a potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia.Journal of Experimental Medicine, 1990